|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 401/04 | (2006.01) |
| A61K 31/4439 | (2006.01) | ||
| A61K 31/4184 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2858985 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13800681.2 |
| Date of filing the European patent application | 2013-06-04 | |
| (97) | Date of publication of the European application | 2015-04-15 |
| (45) | Date of publication and mention of the grant of the patent | 2018-04-18 |
| (46) | Date of publication of the claims translation | 2018-09-25 |
| (86) | Number | PCT/US2013/044116 |
| Date | 2013-06-04 |
| (87) | Number | WO 2013/184681 |
| Date | 2013-12-12 |
| (30) | Number | Date | Country code |
| 201261656888 P | 2012-06-07 | US |
| (72) |
SMITH, Nicholas, D., US
HERBERT, Mark, R., US
OUERFELLI, Ouathek, US
DILHAS, Anna, CH
|
| (73) |
Sloan-Kettering Institute for Cancer Research,
1275 York Avenue, New York, NY 10065,
US
Aragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 301, San Diego, CA 92130, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Kristalinės androgeno receptoriaus moduliatoriaus formos |
| CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR |
| Payment date | Validity (years) | Amount | |
| 2025-05-05 | 13 | 289.00 EUR |
| 2026-06-04 |